Actuate Therapeutics, Inc. Common stock ACTU R2K
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -3.4% CAGR over 5 years.
- Trading 83.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACTU Actuate Therapeutics, Inc. Common stock R2K | 2.02 | - | $48.33M | - | - | - | - | -3.42% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 6.37M | 5.97M | 5.47M | 4.69M | 5.71M |
| Operating Income | - | -5.58M | -6.48M | -7.77M | -5.44M | - | - | -6.37M | -5.97M | -5.47M | -4.69M | -5.71M |
| EBITDA | - | - | - | - | - | - | - | -6.31M | -5.94M | -5.40M | -4.55M | -5.62M |
| Interest Expense | - | - | - | - | - | - | - | 5.06K | 5.06K | 5.06K | 5.06K | 5.06K |
| Pretax Income | - | - | - | - | - | - | - | -6.32M | -5.95M | -5.41M | -4.55M | -5.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.27M | -5.52M | -6.34M | -8.30M | -6.57M | - | - | -6.32M | -5.95M | -5.41M | -4.55M | -5.63M |
| Diluted EPS | - | -3.88 | -4.31 | -5.40 | -4.20 | -0.55 | - | -0.32 | -0.30 | -0.25 | - | -0.24 |
| R&D Expense | - | 4.78M | 5.76M | 6.86M | 4.37M | 3.76M | - | 3.22M | 2.76M | 2.18M | - | 2.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.50M |
| Operating Income | -20.21M | -24.97M | -25.16M | -22.50M |
| EBITDA | -20.14M | -24.70M | -27.27M | -22.21M |
| Interest Expense | 16.20K | 43.64K | 18.72K | 20.25K |
| Pretax Income | -20.16M | -24.74M | -27.29M | -22.23M |
| Tax Provision | - | - | - | - |
| Net Income | -20.16M | -24.74M | -27.29M | -22.23M |
| Diluted EPS | -1.34 | -1.29 | -3.26 | - |
| R&D Expense | - | 21.71M | 18.68M | 10.29M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -3.42% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -83.03% |
| 6 Months: | -67.68% |
| 3 Months: | -45.99% |
| 1 Month: | -29.86% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 20.48M | 3.00M | 9.32M | 14.04M |
| Current Assets | 20.48M | 3.00M | 9.21M | 13.64M |
| Cash & Equivalents | 20.45M | 2.96M | 8.64M | 13.16M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 95.79M | 102.62M | 9.21M | 6.11M |
| Current Liabilities | 4.34M | 6.92M | 8.80M | 5.71M |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | - | - |
| Total Equity | -75.31M | -99.63M | 104.19K | 7.92M |
| Shares Outstanding | 19.11M | 19.11M | 19.53M | 23.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -17.79M | -21.63M | -21.84M | -19.21M |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -17.79M | -21.63M | -21.84M | -19.21M |
| Net Change in Cash | 1.46M | -17.49M | 5.68M | 4.52M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 26.8% | 24.8% | -26,189.1% | -280.5% |
| ROCE % | -125.2% | 636.3% | -4,876.6% | -270.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bios Capital Management, LP | 42.00% | 10.05M | $20.30M |
| 2 | Voss Capital, LP | 7.21% | 1.73M | $3.48M |
| 3 | Blackrock Inc. | 1.79% | 427.15K | $862.85K |
| 4 | Vanguard Capital Management LLC | 1.67% | 400.53K | $809.07K |
| 5 | Geode Capital Management, LLC | 0.95% | 228.33K | $461.23K |
| 6 | Connective Capital Management LLC | 0.47% | 113.27K | $228.80K |
| 7 | Palogic Value Management, LP | 0.42% | 100.00K | $202.00K |
| 8 | Northern Trust Corporation | 0.41% | 97.85K | $197.66K |
| 9 | Texas Capital Bank Wealth Management Services, Inc. | 0.40% | 94.59K | $191.07K |
| 10 | State Street Corporation | 0.28% | 66.03K | $133.38K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACTU